dc.date.accessioned | 2023-03-16T16:17:48Z | |
dc.date.available | 2023-03-16T16:17:48Z | |
dc.date.created | 2022-11-17T13:08:54Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Aghcheli, Bahman Behboudi, Emad Tabarraei, Alijan Razavi Nikoo, Hadi Rajabi, Abdolhalim Moradi, Abdolvahab Nakstad, Britt Tahamtan, Alireza . Serum cytokine/chemokine profile and clinical/paraclinical data in COVID-19 deceased and recovered patients. European Journal of Inflammation. 2022, 20, 1-16 | |
dc.identifier.uri | http://hdl.handle.net/10852/101528 | |
dc.description.abstract | Objectives: The induction of an intense immune response and cytokine storm is proposed to be central in the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study evaluated serum cytokine/chemokine profiles, and clinical and paraclinical data of COVID-19 deceased and recovered patients in Iran. Methods: The severity of disease, clinical data, and routine laboratory and inflammatory cytokine/chemokine responses were retrospectively explored in 60 in-hospital patients in northern Iran. Characteristics of those who deceased ( n = 30) were compared to recovered ( n = 30), and associations with serum levels of potential disease regulating pro- and anti-inflammatory mediators were studied. Results: The serum levels of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17, IP-10, MIP1-α, MCP1, RANTES, and TNF-α were upregulated in all COVID-19 patients when compared to healthy and gender-matched individuals ( n = 30). Although with no significant difference between deceased and recovered cases, the serum levels of all cytokines/chemokines tended to be higher in the severely diseased non-surviving patients. Association analyses revealed that all cytokine/chemokine levels (except IL-10) significantly affect the disease outcome. Conclusion: This study provides more evidence for the association of cytokine/chemokine levels with the clinical course and outcome of COVID-19. More studies are needed to consider this measurement as an indicator of disease stage and strategy for treatment. | |
dc.language | EN | |
dc.rights | Attribution-NonCommercial 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.title | Serum cytokine/chemokine profile and clinical/paraclinical data in COVID-19 deceased and recovered patients | |
dc.title.alternative | ENEngelskEnglishSerum cytokine/chemokine profile and clinical/paraclinical data in COVID-19 deceased and recovered patients | |
dc.type | Journal article | |
dc.creator.author | Aghcheli, Bahman | |
dc.creator.author | Behboudi, Emad | |
dc.creator.author | Tabarraei, Alijan | |
dc.creator.author | Razavi Nikoo, Hadi | |
dc.creator.author | Rajabi, Abdolhalim | |
dc.creator.author | Moradi, Abdolvahab | |
dc.creator.author | Nakstad, Britt | |
dc.creator.author | Tahamtan, Alireza | |
cristin.unitcode | 185,53,46,0 | |
cristin.unitname | Barne- og ungdomsklinikken | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2075595 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European Journal of Inflammation&rft.volume=20&rft.spage=1&rft.date=2022 | |
dc.identifier.jtitle | European Journal of Inflammation | |
dc.identifier.volume | 20 | |
dc.identifier.doi | https://doi.org/10.1177/1721727X221125436 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1721-727X | |
dc.type.version | PublishedVersion | |
cristin.articleid | 1721727X2211254 | |